Fracture rate in patients with myasthenia gravis: the general practice research database

被引:14
|
作者
Pouwels, S. [1 ]
de Boer, A. [1 ]
Javaid, M. K. [2 ]
Hilton-Jones, D. [3 ]
Verschuuren, J. [4 ]
Cooper, C. [2 ,5 ]
Leufkens, H. G. [1 ]
de Vries, F. [1 ,5 ,6 ]
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[2] Univ Oxford, Oxford NIHR Musculoskeletal Biomed Res Unit, Dept Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England
[3] Univ Oxford, Dept Clin Neurol, Oxford, England
[4] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands
[5] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[6] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands
关键词
Corticosteroids; Epidemiology; Fracture; Myasthenia gravis; Osteoporosis; ORAL CORTICOSTEROIDS; RISK; FALLS; ANTIDEPRESSANTS; POPULATION; DRUGS; VALIDATION; DENSITY; WOMEN; MEN;
D O I
10.1007/s00198-012-1970-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to evaluate fracture risk after onset of myasthenia gravis using the UK General Practice Research Database. Overall fracture risk is not statistically increased compared with age- and gender-matched controls irrespective of glucocorticoid use, but was increased in those using antidepressants, anxiolytics or anticonvulsants. Myasthenia gravis (MG) is a neuromuscular disease which has been associated with an increased falls risk and glucocorticoid-induced osteoporosis, recognized determinants of increased fracture risk. The aim of this study was to evaluate the risk of fracture after onset of MG. We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2009). Each MG patient was matched by age, sex, calendar time and practice to up to six patients without a history of MG and we identified all fractures and those associated with osteoporosis. Compared to the control cohort, there was no statistically significant increased risk observed in patients with MG for any fracture (adjusted hazard ratio [AHR] 1.11; 95 % confidence interval [CI], 0.84-1.47) or osteoporotic fractures (AHR 0.98 [95 % CI 0.67-1.41]). Further, use of oral glucocorticoids up to a cumulative dose exceeding 5 g prednisolone equivalents did not increase risk of osteoporotic fracture (AHR 0.99 [95 % CI, 0.31-3.14]) compared with MG patients without glucocorticoid exposure. However, fracture risk was higher in patients with MG prescribed antidepressants (AHR 3.27 [95 % CI, 1.63-6.55]), anxiolytics (AHR 2.18 [95 % CI, 1.04-4.57]) and anticonvulsants (AHR 6.88 [95 % CI, 2.91-16.27]). Overall risk of fracture in patients with MG is not statistically increased compared with age- and gender-matched controls irrespective of glucocorticoid use but was increased in those using antidepressants, anxiolytics or anticonvulsants. These findings have implications in strategies preserving bone health in patients with MG.
引用
收藏
页码:467 / 476
页数:10
相关论文
共 50 条
  • [41] User Involvement in Myasthenia Gravis Research
    Gilhus, Nils Erik
    Hovland, Sandra Iren Barkas
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [42] COGNITION IN PATIENTS WITH MYASTHENIA GRAVIS
    Kawabe, Kiyokazu
    Ikeda, Ken
    Yoshii, Yasuhiro
    Iwasaki, Yasuo
    MUSCLE & NERVE, 2010, 42 (01) : 148 - 148
  • [43] Fatigue in patients with myasthenia gravis
    Alekseeva, T. M.
    Gavrilov, Y. V.
    Kreis, O. A.
    Valko, P. O.
    Weber, K. P.
    Valko, Y.
    JOURNAL OF NEUROLOGY, 2018, 265 (10) : 2312 - 2321
  • [44] Research advancement in immunopathogenesis of myasthenia gravis
    Huang, Sha
    Tan, Li-Ming
    NEUROSCIENCE BULLETIN, 2010, 26 (01) : 85 - 89
  • [45] The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis
    Safipour, Zohreh
    van Der Zanden, Rogier
    van den Bergh, Joop
    Janssen, Paddy
    Vestergaard, Peter
    de Vries, Frank
    Driessen, Johanna H. M.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (03) : 649 - 658
  • [46] The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis
    Zohreh Safipour
    Rogier van der Zanden
    Joop van den Bergh
    Paddy Janssen
    Peter Vestergaard
    Frank de Vries
    Johanna H. M. Driessen
    Osteoporosis International, 2022, 33 : 649 - 658
  • [47] CURRENT STATUS OF RESEARCH ON MYASTHENIA GRAVIS
    NASTUK, WL
    PLESCIA, OJ
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1966, 135 (A1) : 664 - &
  • [48] Fracture risk in patients receiving concomitant bisphosphonate and proton pump inhibitors or bisphosphonates alone: The UK general practice research database
    de Vries, Frank
    Cooper, Alun
    Logan, Richard
    Cockle, Sarah
    Cooper, Cyrus
    van Staa, Tjeerd-Pieter
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S151 - S151
  • [49] Cause of Death in Patients with Multiple Sclerosis and Controls: The General Practice Research Database
    Lalmohamed, Arief
    Bazelier, Marloes T.
    van Staa, Tjeerd P.
    de Vries, Frank
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S276 - S276
  • [50] Cause of death in patients with multiple sclerosis and controls: the General Practice Research Database
    Bazelier, M. T.
    Lalmohamed, A.
    van Staa, T.
    Uitdehaag, B.
    Leufkens, H.
    de Vries, F.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S86 - S86